Advanced Search
YANG Liping, LI Fuxing, LI Wengui. Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 505-509. DOI: 10.3971/j.issn.1000-8578.2018.17.1689
Citation: YANG Liping, LI Fuxing, LI Wengui. Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(7): 505-509. DOI: 10.3971/j.issn.1000-8578.2018.17.1689

Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer

  • The morbidity of prostate cancer (PCa) is high. Early diagnosis of recurrence after primary treatment is very important for the prognosis. Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein, with high expression in PCa. Small molecule inhibitors of the PSMA is labeled by 68Ga(68Ga-PSMA). 68Ga-PSMA is used as imaging agent for PET/CT imaging. 68Ga-PSMA PET/CT can display the distribution of prostate cancer in vivo. Many European and American countries have used 68Ga-PSMA PET/CT to find recurrent lesions in prostate cancer patients and achieved good results. This technology is still in its initial stage in China. This article reviews the research progress of 68Ga-PSMA PET/CT in prostate cancer recurrence, in order to improve the understanding of this new technology in China.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return